Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Seminoma Stage I Followed with Surveillance

Authors

  • Finn Edler von Eyben From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Ebbe Lindegaard Madsen From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Ole Blaabjerg From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Per Hyltoft Petersen From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Grete Krag Jacobsen From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Lena Specht From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Bent Nørgaard Pedersen From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark
  • Hans von Der Maase From the Departments of Clinical Chemistry (F.E. von Eyben, O. Blaabjerg, P.H. Petersen) and Oncology (E.L. Madsen), Odense University Hospital, Odense, Department of Pathology, Gentofte University Hospital (G.K. Jacobsen), Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital (L. Specht), Department of Clinical Biochemistry, Statens Serum Institut (B. Nrgaard Pedersen) and Department of Oncology, Arhus University Hospital (H. von der Maase), Denmark

DOI:

https://doi.org/10.1080/028418602317314109

Abstract

Serum lactate dehydrogenase isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (p=0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (p=0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

von Eyben, F. E., Madsen, E. L., Blaabjerg, O., Petersen, P. H., Jacobsen, G. K., Specht, L., … von Der Maase, H. (2002). Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Seminoma Stage I Followed with Surveillance. Acta Oncologica, 41(1), 77–83. https://doi.org/10.1080/028418602317314109

Issue

Vol. 41 No. 1 (2002): Acta Oncologica

Section

Articles